Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31567960 | 0.79 | ALDH1A1 (0.30) | ALDH1A1LMNATP53TSHR | |
| SCHEMBL28992346 | 0.79 | ALDH1A1 (0.30) | ALDH1A1LMNATP53TSHR | |
| SCHEMBL31567967 | 0.75 | PRSS1 (0.35) | — | |
| SCHEMBL7220266 | 0.69 | ALDH1A1 (0.31) | ALDH1A1LMNATP53TSHR | |
| SCHEMBL29176239 | 0.67 | — | — | |
| SCHEMBL16770277 | 0.63 | — | — | |
| SCHEMBL28447016 | 0.62 | TLR4 (0.33) | ALDH1A1LMNATP53TSHR | |
| SCHEMBL30665398 | 0.61 | ALDH1A1 (0.30) | ALDH1A1LMNATP53TSHR | |
| SCHEMBL28617732 | 0.57 | — | — | |
| SCHEMBL15661377 | 0.55 | TLR4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| CN-118930561-B | Condensed ring compound | 上海信诺维生物医药有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-118930561-A | Condensed ring compound | 上海信诺维生物医药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118345390-A | Method for preparing carbonyl compound by electrocatalytic oxidation of benzyl C-H bond by pyridine nitrogen oxide | 浙江大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-116891488-A | Condensed-cyclic compound, pharmaceutical composition containing condensed-cyclic compound and application of condensed-cyclic compound | 成都海博为药业有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | ALDH1A1 3098/4885LMNA 3838/4885TP53 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.